COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN COLOMBIA

被引：0
|
作者：
Lacey, M. [1 ]
Brouillette, M. [1 ]
Karpf, E. [2 ]
Lenhart, G. [1 ]
Barbeau, M. [3 ]
Russell, M. [1 ]
机构：
[1] Truven Hlth Analyt, Cambridge, MA USA
[2] Novartis Colombia, Bogota, Colombia
[3] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1218
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV72
引用
收藏
页码：A613 / A613
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN BRAZIL
    Lacey, M.
    Brouillette, M.
    Libanore, A.
    Lenhart, G.
    Tozato, C.
    Lopes, N.
    Russell, M.
    VALUE IN HEALTH, 2018, 21 : S63 - S63
  • [2] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN COSTA RICA
    Lacey, M. J.
    Brouillette, M.
    Lenhart, G.
    Hernandez Matamoros, H.
    Quesada Chaves, D. F.
    Bonilla Sinibaldi, F.
    Russell, M. W.
    VALUE IN HEALTH, 2018, 21 : S60 - S60
  • [3] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    HEART, 2018, 104 (12) : 1006 - 1013
  • [4] Cost-effectiveness analyses of sacubitril-valsartan for heart failure
    Liu, Xiao-qi
    He, Li-shan
    Huang, Jian-qing
    Xiong, Ling-juan
    Xia, Chen
    Lao, Hai-yan
    HEART FAILURE REVIEWS, 2021, 26 (05) : 1119 - 1130
  • [5] Cost-effectiveness analyses of sacubitril-valsartan for heart failure
    Xiao-qi Liu
    Li-shan He
    Jian-qing Huang
    Ling-juan Xiong
    Chen Xia
    Hai-yan Lao
    Heart Failure Reviews, 2021, 26 : 1119 - 1130
  • [6] COMPARISON OF COST-EFFECTIVENESS BETWEEN SACUBITRIL/VALSARTAN AND VALSARTAN WITH ENALAPRIL IN HEART FAILURE
    Earla, J. R.
    Sansgiry, S. S.
    VALUE IN HEALTH, 2019, 22 : S124 - S124
  • [7] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE
    Declan, L.
    Tang, Z. X.
    Ng, C.
    Tan, J.
    Trueman, D.
    Woodcock, F.
    Cristino, J.
    VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [8] COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/ VALSARTAN IN HEART FAILURE PATIENTS IN EGYPT
    Khalil, A.
    Elsisi, G.
    Mahdy, M. Abdel Meguid
    Mansy, S.
    Farouk, M.
    Seleem, M.
    Nassar, A.
    VALUE IN HEALTH, 2024, 27 (12)
  • [9] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN TURKEY
    Sarioz, F.
    Ozdemir, O.
    Direk, S.
    Caglar, P.
    Ar, I
    VALUE IN HEALTH, 2017, 20 (09) : A616 - A616
  • [10] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
12345